ArticleLancet (London, England)2020
Remdesivir for COVID-19: challenges of underpowered studies.
Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.Drug design, development and therapy · 2022Pooled it
- Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.Journal of critical care · 2020Pooled it
- Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.The New England journal of medicine · 2020Trial
- Article
- Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.Molecules (Basel, Switzerland) · 2024Review
- Adjusted green spectrophotometric determination of favipiravir and remdesivir in pharmaceutical form and spiked human plasma sample using different chemometric supported models.BMC chemistry · 2023Article
- Setomimycin as a potential molecule for COVID‑19 target: in silico approach and in vitro validation.Molecular diversity · 2023Article
- COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.BioMed research international · 2023Review
- A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.Narra J · 2022Review
- An ordinal severity scale for COVID-19 retrospective studies using Electronic Health Record data.JAMIA open · 2022Article
- Spectrophotometric quantitative analysis of remdesivir using acid dye reagent selected by computational calculations.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2022Article
- "Don't Look Up" Your Science-Herd Immunity or Herd Mentality?Microorganisms · 2022Article
- Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19.Scientific reports · 2022Article
- Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.Journal of medicinal chemistry · 2022Review
- Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients.Journal of medical virology · 2022Article
- Article
- Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges.Beni-Suef University journal of basic and applied sciences · 2022Review
- Article
- Fake or real news about COVID-19? Pretrained transformer model to detect potential misleading news.The European physical journal. Special topics · 2022Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.